|1.||Matsushita, Fumio: 1 article (07/2012)|
|2.||Kitagawa, Hitoshi: 1 article (07/2012)|
|3.||Ozeki, Yasuhiro: 1 article (07/2012)|
|4.||Fujimura, Yoshihiro: 1 article (07/2012)|
|5.||Matsumoto, Masanori: 1 article (07/2012)|
|6.||Matsui, Taei: 1 article (07/2012)|
|7.||Yamamoto-Suzuki, Yukiyo: 1 article (07/2012)|
|8.||Sakurai, Yoshihiko: 1 article (07/2012)|
|9.||Kokubo, Tetsuro: 1 article (07/2012)|
|10.||Fujii, Yuki: 1 article (07/2012)|
|1.||von Willebrand Diseases (von Willebrand's Disease)
06/01/1995 - "A second group of animals (2 dogs and 3 pigs) with von Willebrand disease (vWD) was given a single botrocetin injection (90 to 100 U/kg). "
10/05/1992 - "Present data indicate that purified two-chain botrocetin binds to vWF from plasmas of patients with type IIA or IIB von Willebrand disease and its interaction is indistinguishable from that with vWF from normal individuals. "
08/15/1994 - "The quantitative determinations of von Willebrand Factor (vWF)-Ristocetin cofactor (vWF:RCof) and the Botrocetin cofactor (vWF:BCof) are important parameters for the diagnosis of von Willebrand's disease. "
10/15/1992 - "The normal botrocetin-induced binding and the defective ristocetin-induced binding of rvWF(G561S) suggest that the primary defect in von Willebrand disease type B may be a failure of normal allosteric regulation of the glycoprotein Ib binding function of vWF."
10/15/1992 - "A missense mutation, Gly-561-->Ser, was identified within the proposed glycoprotein Ib binding domain of vWF in the proband with von Willebrand disease type B, a unique variant characterized by no ristocetin-induced, but normal botrocetin-induced, binding to glycoprotein Ib. "
|2.||Type 2 von Willebrand Disease
01/31/1992 - "Three point mutations associated with human type IIB von Willebrand disease in the first segment of a botrocetin binding site are at the same position as mismatches between the pig and human. "
02/01/2003 - "A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease."
03/01/1998 - "Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets."
|3.||Activated Protein C Resistance (APC Resistance)
05/01/2001 - "Protein C (PC) and activated PC (APC) resistance can be measured by means of RVV, Protac (from Southern copperhead snake venom) and STA-Staclot (from Crotalus viridis helleri) whilst von Willebrand factor can be studied with Botrocetin (Bothrops jararaca). "
06/15/2005 - "Protein C and activated protein C resistance can be measured by means of RVV and Protac, a fast acting inhibitor from Southern copperhead snake venom and von Willebrand factor can be studied with botrocetin from Bothrops jararaca venom. "
07/01/1998 - "Protein C and activated protein C resistance can be measured by means of RVV and Protac, a fast acting inhibitor from Southern copperhead snake venom and von Willebrand factor can be studied with Botrocetin from Bothrops jararaca venom. "
06/01/2003 - "Intravenous administration of a monoclonal antibody against vWF (AJW200, 1.0 mg/kg body weight) remarkably prevented botrocetin-induced platelet aggregation ex vivo for 2 days; moreover, thrombus formation, cell proliferation, and subsequent neointimal growth were significantly reduced at 30 minutes, 5 days, and 4 weeks, respectively, after the second balloon injury. "
07/03/2012 - "Since it has been time-consuming and difficult to obtain homogeneous botrocetin from natural venom, recombinant botrocetin-2 has potential benefits for clinical and basic investigations into hemostasis and thrombosis as a standard reagent."
10/15/2006 - "Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo."
06/01/1995 - "However, both animals developed thrombotic thrombocytopenia when injected with botrocetin. "
10/01/1988 - "A comparison is made of the thrombocytopenia and the ultrastructure of the platelet microthrombi induced by botrocetin with that of other agents."
10/01/1988 - "After each botrocetin administration (single or repeat), a transient thrombocytopenia developed which was most severe at 1 to 5 hours postinjection. "
10/01/1988 - "The vWF deficiency state with thrombocytopenia was produced in 12 animals by single or multiple injections of botrocetin. "
06/01/1995 - "Thrombotic thrombocytopenia with severe depletion of plasma von Willebrand factor (vWF) was induced in normal large animals (5 dogs and 2 pigs) by botrocetin, a Bothrops factor requiring vWF for platelet agglutination. "
|1.||von Willebrand Factor
|3.||Snake Venoms (Snake Venom)
|6.||snake venom protein C activator
|7.||Platelet Glycoprotein GPIb-IX Complex (Glycoprotein Ib)
|8.||Protein-Tyrosine Kinases (Tyrosine Kinase)